Changes in the perceived epidemiology of primary hyperaldosteronism

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Fagugli, Riccardo Maria ^a   Taglioni, Chiara ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; EPLERENONE;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG SENSITIVITY; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; SYSTEMATIC REVIEW;

EID: 84868266958     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/162804     Document Type: Review

References (47)

1. Conn J. W., Presidential address. Part I. Painting background Part II. Primary aldosteronism, a new clinical syndrome. The Journal of Laboratory and Clinical Medicine 1955 45 1 3 17 2-s2.0-2342642610
2. Fishman L. M., Küchel O., Liddle G. W., Michelakis A. M., Gordon R. D., Chick W. T., Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. Journal of the American Medical Association 1968 205 7 497 502 2-s2.0-0014411839 10.1001/jama.205.7.497
3. Kaplan N. M., Commentary on incidence of primary aldosteronism: current estimations based on objective data. Archives of Internal Medicine 1969 123 2 152 154 2-s2.0-0014465304
4. Funder J. W., Carey R. M., Fardella C., Case detection, dsiagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 2008 93 3266 3288
5. Gordon R. D., Primary aldosteronismactual epidemics or false alarm? Arquivos Brasileiros de Endocrinologia e Metabologia 2004 48 5 666 673 2-s2.0-15944383626
6. Moraitis A., Stratakis C., Adrenocortical causes of hypertension. International Journal of Hypertension 2011 2011 10.4061/2011/624691 624691
7. Calhoun D. A., Aldosteronism and hypertension. Clinical journal of the American Society of Nephrology 2006 1 5 1039 1045 2-s2.0-34250184021 10.2215/CJN.01060306
8. Weinberger M. H., Roniker B., Krause S. L., Weiss R. J., Eplerenone, a Selective Aldosterone Blocker, in mild-to-moderate hypertension. American Journal of Hypertension 2002 15 8 709 716 2-s2.0-0035997359 10.1016/S0895- 7061(02)02957-6 (Pubitemid 34804277)
9. Krum H., Nolly H., Workman D., He W., Roniker B., Krause S., Fakouhi K., Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002 40 2 117 123 2-s2.0-0036330671 10.1161/01.HYP. 0000025146.19104.FE (Pubitemid 34840085)
10. Prisant L. M., Krum H., Roniker B., Krause S. L., Fakouhi K., He W., Can renin status predict the antihypertensive efficacy of eplerenone add-On therapy? Journal of Clinical Pharmacology 2003 43 11 1203 1210 2-s2.0-0142103700 10.1177/0091270003258189 (Pubitemid 37280791)
11. Weir M. R., Rolfe M., Potassium homeostasis and renin-angiotensin- aldosterone system inhibitors. Clinical Journal of the American Society of Nephrology 2010 5 3 531 548 2-s2.0-77749292028 10.2215/CJN.07821109
12. Eide I. K., Torjesen P. A., Drolsum A., Babovic A., Lilledahl N. P., Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. Journal of Hypertension 2004 22 11 2217 2226 2-s2.0-7744227337 10.1097/00004872-200411000-00026 (Pubitemid 39463817)
13. Vasan R. S., Evans J. C., Larson M. G., Wilson P. W. F., Meigs J. B., Rifai N., Benjamin E. J., Levy D., Serum aldosterone and the incidence of hypertension in nonhypertensive persons. The New England Journal of Medicine 2004 351 1 33 111 2-s2.0-3042731163 10.1056/NEJMoa033263 (Pubitemid 38857245)
14. Newton-Cheh C., Guo C. Y., Gona P., Larson M. G., Benjamin E. J., Wang T. J., Kathiresan S., O'Donnell C. J., Musone S. L., Camargo A. L., Drake J. A., Levy D., Hirschhorn J. N., Vasan R. S., Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007 49 4 846 856 2-s2.0-34047233709 10.1161/01.HYP. 0000258554.87444.91 (Pubitemid 351664212)
15. Furumatsu Y., Nagasawa Y., Tomida K., Mikami S., Kaneko T., Okada N., Tsubakihara Y., Imai E., Shoji T., Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin- converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research 2008 31 1 59 67 2-s2.0-40149090641 10.1291/hypres.31.59 (Pubitemid 351325616)
16. Nishiyama A., Yao L., Fan Y., Kyaw M., Kataoka N., Hashimoto K., Nagai Y., Nakamura E., Yoshizumi M., Shokoji T., Kimura S., Kiyomoto H., Tsujioka K., Kohno M., Tamaki T., Kajiya F., Abe Y., Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005 45 4 710 716 2-s2.0-20144365498 10.1161/01.HYP.0000154681.38944.9a (Pubitemid 40418370)
17. Conn J. W., The evolution of primary aldosteronism: 19541967. Harvey Lectures 1966 62 257 291 2-s2.0-0013989444
18. Gordon R. D, Ziesak M. D., Tunyy T. J., Evidence that primary aldosteronism may not be uncommon: 12 incidence among hypertensive drug trial volunteers. Clinical and Experimental Pharmacology and Physiology 1993 20 296 298 (Pubitemid 23140199)
19. Gordon R. D, Stowasser M. D., Tunyy T. J., High prevalence in primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology 1994 21 315 318 (Pubitemid 24201225)
20. Fardella C. E., Mosso L., Gomez-Sanchez C., Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. The Journal of Clinical Endocrinology & Metabolism 2000 85 1863 1867 (Pubitemid 32269290)
21. Olivieri O., Ciacciarelli A., Signorelli D., Aldosterone to Renin Ratio in a primary care setting: the Bussolengo Study. The Journal of Clinical Endocrinology & Metabolism 2004 89 4421 4426
22. Rossi G. P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M., Mallamaci F., Mannelli M., Mattarello M. J., Moretti A., Palumbo G., Parenti G., Porteri E., Semplicini A., Rizzoni D., Rossi E., Boscaro M., Pessina A. C., Mantero F., A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 2006 48 11 2293 2300 2-s2.0-33748132658 10.1016/j.jacc.2006.07.059 (Pubitemid 44873058)
23. Williams J. S., Williams G. H., Raji A., Jeunemaitre X., Brown N. J., Hopkins P. N., Conlin P. R., Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. Journal of Human Hypertension 2006 20 2 129 136 2-s2.0-31444435586 10.1038/sj.jhh.1001948 (Pubitemid 43148614)
24. Calhoun D. A., Nishizaka M. K., Zaman M. A., Thakkar R. B., Weissmann P., Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002 40 6 892 896 2-s2.0-0036898286 10.1161/01.HYP.0000040261. 30455.B6 (Pubitemid 35434912)
25. Gallay B. J., Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. American Journal of Kidney Diseases 2001 37 4 699 705 2-s2.0-0035057456 (Pubitemid 32268029)
26. Strauch B., Zelinka T., Hampf M., Prevalence of primary aldosteronism in moderate to severe hypertension in the Central Europe region. Journal of Human Hypertension 2003 17 349 352 (Pubitemid 36625965)
27. Di Murro A., Petramala L., Cotesta D., Zinnamosca L., Crescenzi E., Marinelli C., Saponara M., Letizia C., Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System 2010 11 3 165 172 2-s2.0-77956300089 10.1177/1470320310366581
28. Mukherjee J. J., Khoo C. M., Thai A. C., Chionh S. B., Pin L., Lee K. O., Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism. Diabetes and Vascular Disease Research 2010 7 1 6 13 2-s2.0-77949362078 10.1177/1479164109350556
29. Umpierrez G. E., Cantey P., Smiley D., Palacio A., Temponi D., Luster K., Chapman A., Primary Aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007 30 7 1699 1703 2-s2.0-34447136684 10.2337/dc07-0031 (Pubitemid 47036339)
30. Montori V. M., Young W. F., Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: A systematic review of the literature. Endocrinology and Metabolism Clinics of North America 2002 31 3 619 632 2-s2.0-0036713825 10.1016/S0889-8529(02)00013-0 (Pubitemid 35006613)
31. Kaplan N. M., Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 2007 50 3 454 458 2-s2.0-34548644501
32. Mosso L., Carvajal C., González A., Barraza A., Avila F., Montero J., Huete A., Gederlini A., Fardella C. E., Primary aldosteronism and hypertensive disease. Hypertension 2003 42 2 161 165 2-s2.0-0042266234 10.1161/01.HYP.0000079505.25750.11 (Pubitemid 36944590)
33. Rossi G. P., Seccia T. M., Palumbo G., Belfiore A., Bernini G., Caridi G., Desideri G., Fabris B., Ferri C., Giacchetti G., Letizia C., MacCario M., Mallamaci F., Mannelli M., Patalano A., Rizzoni D., Rossi E., Pessina A. C., Mantero F., Within-patient reproducibility of the aldosterone:renin ratio in primary aldosteronism. Hypertension 2010 55 1 83 89 2-s2.0-73849090218 10.1161/HYPERTENSIONAHA.109.139832
34. Hiroara D., Nomura K., Okamoto T., Performance of the basal aldosterone to renin ratio and of renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low-renin hypertensives. The Journal of Clinical Endocrinology & Metabolism 2001 86 4292 4298 (Pubitemid 32848549)
35. Eide I. K., Torjesen P. A., Drolsum A., Babovic A., Lilledahl N. P., Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. Journal of Hypertension 2004 22 11 2217 2226 2-s2.0-7744227337 10.1097/00004872-200411000-00026 (Pubitemid 39463817)
36. Pratt-Ubunama M. N., Nishizaka M. K., Boedefeld R. L., Cofield S. S., Harding S. M., Calhoun D. A., Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007 131 2 453 459 2-s2.0-33847193562 10.1378/chest.06-1442
37. Goodfriend T. L., Calhoun D. A., Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004 43 3 518 524 2-s2.0-1442338287 10.1161/01.HYP.0000116223.97436.e5 (Pubitemid 38282420)
38. Saydah S. H., Fradkin J., Cowie C. C., Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Journal of the American Medical Association 2004 291 3 335 342 2-s2.0-0347133334 10.1001/jama.291.3.335 (Pubitemid 38101606)
39. Adler A. I., Stratton I. M., Neil H. A. W., Yudkin J. S., Matthews D. R., Cull C. A., Wright A. D., Turner R. C., Holman R. R., Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. British Medical Journal 2000 321 7258 412 419 2-s2.0-0034641550 (Pubitemid 30609443)
40. Milliez P., Girerd X., Plouin P. F., Blacher J., Safar M. E., Mourad J. J., Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 8 1243 1248 2-s2.0-17144421237 10.1016/j.jacc.2005.01.015 (Pubitemid 40523144)
41. Catena C., Colussi G., Lapenna R., Nadalini E., Chiuch A., Gianfagna P., Sechi L. A., Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007 50 5 911 918 2-s2.0-35848931662 10.1161/HYPERTENSIONAHA.107.095448 (Pubitemid 350287534)
42. Funder J., Mineralcorticoids and cardiac fibrosis. Clinical and Experimental Pharmacology and Physiology 2001 28 1002 1006
43. Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R., Sechi L. A., Cardiovascular outcomes in patients with primary aldosteronism after treatment. Archives of Internal Medicine 2008 168 1 80 85 2-s2.0-38349079854 10.1001/archinternmed.2007.33
44. Born-Frontsberg E., Reinke M., Rump L. C., Cardiovascular and cerebrovascular comorbidities of hypokaliemic and normokalemic primary aldosteronism: results of the German Conn's Registry. The Journal of Clinical Endocrinology & Metabolism 2009 94 1125 1130
45. Tomaschitz A., Pilz S., Ritz E., Meinitzer A., Boehm B. O., März W., Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. European Heart Journal 2010 31 10 1237 1247 2-s2.0-77952395275 10.1093/eurheartj/ehq019
46. Pitt B., Zannad F., Remme W. J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized Aldactone Study Investigators. The New England Journal of Medicine 1999 341 709 717 (Pubitemid 29407370)
47. Navaneethan S. D., Nigwekar S. U., Sehgal A. R., Strippoli G. F. M., Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology 2009 4 3 542 551 2-s2.0-66149131479 10.2215/CJN.04750908